Fortress Biotech (FBIO) closed at $1.85 on November 6, 2026, up 0.5% from the previous close, on volume of 127,281 shares (30-day average 230,819).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire (Thu, 5-Nov 8:30 AM ET)
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Globe Newswire (Tue, 8-Sep 4:05 PM ET)
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Globe Newswire (Wed, 12-Aug 4:01 PM ET)
Market Chameleon (Mon, 23-Feb 4:56 AM ET)
Market Chameleon (Mon, 15-Dec 6:06 AM ET)
Legal Probe Launched into Fortress Biotech as FDA Letter Raises Concerns
Market Chameleon (Thu, 2-Oct 7:23 AM ET)
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
Fortress Biotech trades on the NASDAQ stock market under the symbol FBIO.
As of November 9, 2026, FBIO stock price climbed to $1.97 with 78,210 million shares trading.
FBIO has a beta of 0.53, meaning it tends to be less sensitive to market movements. FBIO has a correlation of 0.02 to the broad based SPY ETF.
FBIO has a market cap of $65.70 million. This is considered a Micro Cap stock.
Last quarter Fortress Biotech reported $19 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $418,000 and exceeded earnings estimates by $.12.
In the last 3 years, FBIO traded as high as $4.53 and as low as $1.24.
The top ETF exchange traded funds that FBIO belongs to (by Net Assets): VTI, VXF, IWC, BSVO, AVSC.
FBIO has underperformed the market in the last year with a return of -21.8%, while the SPY ETF gained +12.9%. In the last 3 month period, FBIO fell short of the market, returning -28.9%, while SPY returned -2.2%. However, in the most recent 2 weeks FBIO has outperformed the stock market by returning +2.1%, while SPY returned -1.4%.
FBIO support price is $1.78 and resistance is $1.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FBIO shares will trade within this expected range on the day.
